Senior Science Correspondent for @Endpts covering biotech, drug discovery, gene editing, RNA, and more. Formerly at Boston Globe and C&EN. Threads: ryancross
May 4, 2018 • 5 tweets • 3 min read
So @Merck’s BACE-1 inhibitor Verubecestat resulted in “near-maximal reduction” of amyloid-beta in cerebrospinal fluid and “modest reduction” in brain amyloid. But it didn’t help even #Alzheimer’s disease, even "mild" Alzheimer's. A few thoughts:
1. Many companies are holding on to the hope that giving #tau- and #amyloid-busting drugs earlier, before Alzheimer's sets in, could prevent the disease. The FDA might even be open to using tau and amyloid as biomarkers to approve #Alzheimers drugs cen.acs.org/articles/96/i9…
